Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19

Seoul National University

Status: Completed

Conditions: COVID-19

Treatments: Other: No intervention (Retrospective Cohort Observational)

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04834752

2102-004-1192

Details and patient eligibility

About

This retrospective cohort study aims to evaluate the effect of proton pump inhibitor (PPI) or histamine-2 receptor antagonist (H2RA) on the clinical outcomes and positivity rates of Coronavirus Disease-19 (COVID-19).

Full description

Previous researches on the association between the use of PPI and H2RA and the treatment and prevention of COVID-19 have reported inconsistent findings. This study aimed to evaluate the effect of H2 receptor antagonists and proton pump inhibitors on the clinical outcomes and positivity rates of COVID-19 using the Korean National Health Insurance (NHI) data. This is a retrospective cohort study using the NHI COVID-19 dataset, which includes health insurance data of individuals who underwent COVID-19 PCR test in South Korea. This study aims to evaluate the effect of the use of PPI and H2RA on the positivity rates and clinical outcomes of COVID-19.

Enrollment: 400,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Individuals who were tested for COVID-19 using real-time reverse transcriptase PCR assay of nasal and pharyngeal swabs

Exclusion criteria

• Record of a new prescription of non-steroidal anti-inflammatory drugs (NSAID) within 1 month of the test date
• Patients who died within 48 hours after test.

Trial design

400,000 participants in 1 patient group

Patients tested for COVID-19

Description:

Patients who were tested for COVID-19 nasopharyngeal polymerase chain reaction (PCR)

Treatment:

Other: No intervention (Retrospective Cohort Observational)